VistaGen Therapeutics Surged Nearly 1100% in Morning Trading

Dow Jones2023-08-07

VistaGen Therapeutics surged nearly 1100% in morning trading.

VistaGen Therapeutics said the Phase 3 study of its fasedienol nasal spray as a treatment for social anxiety disorder met its primary endpoint.

The San Francisco-based biopharmaceutical company said the trial evaluated the efficacy, safety and tolerability of fasedienol and, in a public speaking challenge, demonstrated a statistically significant difference in average score of Subjective Units of Distress Scale compared with a placebo.

The trial also met its secondary endpoint and was well-tolerated, with a favorable safety profile consistent with all prior trials.

Researchers will now be looking to conduct a study involving multiple administrations of fasedienol over several weeks.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Ramtin
2023-08-07
Ramtin
Another trap!

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2357323112?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-08-07 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2357323112","market":"us","top_or_hot":-1,"title":"VistaGen Therapeutics Surged Nearly 1100% in Morning Trading","media":"Dow Jones","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/VTGN\">VistaGen Therapeutics</a> surged nearly 1100% in morning trading.</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/87104e20eb39c7dcc0fab317836a6c17\" tg-width=\"631\" tg-height=\"603\"/></p><p>VistaGen Therapeutics said the Phase 3 study of its fasedienol nasal spray as a treatment for social anxiety disorder met its primary endpoint.</p><p>The San Francisco-based biopharmaceutical company said the trial evaluated the efficacy, safety and tolerability of fasedienol and, in a public speaking challenge, demonstrated a statistically significant difference in average score of Subjective Units of Distress Scale compared with a placebo.</p><p>The trial also met its secondary endpoint and was well-tolerated, with a favorable safety profile consistent with all prior trials.</p><p>Researchers will now be looking to conduct a study involving multiple administrations of fasedienol over several weeks.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VistaGen Therapeutics Surged Nearly 1100% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVistaGen Therapeutics Surged Nearly 1100% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-07 21:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VistaGen Therapeutics surged nearly 1100% in morning trading.VistaGen Therapeutics said the Phase 3 study of its fasedienol nasal spray as a treatment for social anxiety disorder met its primary ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTGN","symbol_name":"VistaGen Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2357323112","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2357323112","pubTimestamp":1691415050,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"VistaGen Therapeutics said the Phase 3 study of its fasedienol nasal spray as a treatment for social anxiety disorder met its primary endpoint.The San Francisco-based biopharmaceutical company said the trial evaluated the efficacy, safety and tolerability of fasedienol and, in a public speaking challenge, demonstrated a statistically significant difference in average score of Subjective Units of Distress Scale compared with a placebo.The trial also met its secondary endpoint and was well-tolerated, with a favorable safety profile consistent with all prior trials.Researchers will now be looking to conduct a study involving multiple administrations of fasedienol over several weeks.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTGN":"VistaGen Therapeutics, Inc."},"translate_title":"VistaGen Therapeutics在早盘交易中飙升近1100%","themeId":"b6251d276d524a92990b019863be720e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTGN":0.9},"content_text":"VistaGen Therapeutics surged nearly 1100% in morning trading.VistaGen Therapeutics said the Phase 3 study of its fasedienol nasal spray as a treatment for social anxiety disorder met its primary endpoint.The San Francisco-based biopharmaceutical company said the trial evaluated the efficacy, safety and tolerability of fasedienol and, in a public speaking challenge, demonstrated a statistically significant difference in average score of Subjective Units of Distress Scale compared with a placebo.The trial also met its secondary endpoint and was well-tolerated, with a favorable safety profile consistent with all prior trials.Researchers will now be looking to conduct a study involving multiple administrations of fasedienol over several weeks.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":206374207373520,"gmtCreate":1691416166810,"gmtModify":1691416170068,"author":{"id":"4148272534746172","authorId":"4148272534746172","authorIdStr":"4148272534746172","name":"Ramtin","avatar":"https://community-static.tradeup.com/news/9667c6c075165296371af8ddbd92dae1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4148272534746172"},"htmlText":"Another trap!&nbsp;","listText":"Another trap!&nbsp;","text":"Another trap!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/206374207373520","repostId":2357323112,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":12,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2357323112"}